TrialAnnals of the rheumatic diseases2014

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial.

Christopher Ritchlin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.